Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
- PMID: 9086128
- DOI: 10.1086/513969
Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
Abstract
The inability of antibodies induced by experimental human immunodeficiency virus type 1 (HIV-1) vaccines to neutralize HIV-1 primary isolates may be due to a failure to elicit such antibodies, antigenic differences between the vaccine and the strains tested, insensitivity of the assays used, or to a combination of factors. New neutralization assays were used to determine the ability of candidate AIDS vaccines to generate neutralizing antibodies for clade B primary isolate BZ167, which is closely related in portions of its envelope to the immunizing strains. Sera from HIV-uninfected volunteers in vaccine trials were tested, and neutralizing activity was found in recipients of recombinant (r) gp120MN or of rgp160MN-containing canarypox boosted with rgp120SF-2. Detection of antibodies that neutralize primary isolate BZ167 correlated with neutralizing activity for homologous vaccine strains. These data demonstrate that certain candidate AIDS vaccines can elicit antibodies that neutralize a primary isolate of HIV-1.
Comment in
-
Neutralization assays using the BZ167 strain of human immunodeficiency virus type 1.J Infect Dis. 1997 Nov;176(5):1410-2. doi: 10.1086/514134. J Infect Dis. 1997. PMID: 9359750 No abstract available.
Similar articles
-
A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.J Virol. 2000 Nov;74(21):10025-33. doi: 10.1128/jvi.74.21.10025-10033.2000. J Virol. 2000. PMID: 11024131 Free PMC article. Clinical Trial.
-
Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.AIDS. 1998 Dec 24;12(18):2407-15. doi: 10.1097/00002030-199818000-00009. AIDS. 1998. PMID: 9875578 Clinical Trial.
-
Neutralization of syncytium-inducing primary isolates by sera from human immunodeficiency virus (HIV)-uninfected recipients of candidate HIV vaccines.J Infect Dis. 1998 Nov;178(5):1502-6. doi: 10.1086/314452. J Infect Dis. 1998. PMID: 9780275 Clinical Trial.
-
Human studies in the development of human immunodeficiency virus vaccines.J Infect Dis. 1995 Nov;172(5):1175-83. doi: 10.1093/infdis/172.5.1175. J Infect Dis. 1995. PMID: 7594651 Review.
-
GP120: target for neutralizing HIV-1 antibodies.Annu Rev Immunol. 2006;24:739-69. doi: 10.1146/annurev.immunol.24.021605.090557. Annu Rev Immunol. 2006. PMID: 16551265 Review.
Cited by
-
Strategies for Using Muramyl Peptides - Modulators of Innate Immunity of Bacterial Origin - in Medicine.Front Immunol. 2021 Apr 20;12:607178. doi: 10.3389/fimmu.2021.607178. eCollection 2021. Front Immunol. 2021. PMID: 33959120 Free PMC article. Review.
-
Building and testing an effective HIV vaccine.West J Med. 1999 Nov-Dec;171(5-6):363-5. West J Med. 1999. PMID: 10639877 Free PMC article. Review. No abstract available.
-
Anti-Viral Pattern Recognition Receptors as Therapeutic Targets.Cells. 2021 Aug 31;10(9):2258. doi: 10.3390/cells10092258. Cells. 2021. PMID: 34571909 Free PMC article. Review.
-
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.J Virol. 1998 Feb;72(2):1052-9. doi: 10.1128/JVI.72.2.1052-1059.1998. J Virol. 1998. PMID: 9444999 Free PMC article.
-
Immunomodulatory Nanosystems.Adv Sci (Weinh). 2019 Jun 21;6(17):1900101. doi: 10.1002/advs.201900101. eCollection 2019 Sep 4. Adv Sci (Weinh). 2019. PMID: 31508270 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
